Bristol-Myers posts strong second quarter earnings as Eliquis, Orencia surprise

Bristol-Myers Squibb , which is set to buy biotechnology company Celgene Corp soon for $74 billion, posted better-than-expected second-quarter earnings on Thursday on strong sales from its blood thinner Eliquis and rheumatoid arthritis treatment Orencia.